Biocon plans to list its biosimilars business by March 2026 and aims for a double-digit market share in the U.S. for five new biosimilars l...

“It will be a mix of debt, equity and of course IPO. It is going to be a very interesting business opportunity and a very comfortable aspec...

"And obviously, we expect the IPO to be at a very, very attractive level. So if you look at it, it's going to hugely create value for share...

“We are investing thoughtfully to expand the global footprint step by step across the world. We have opened regional offices across Latin A...

True North has acquired about 3 per cent of Biocon Biologics India Ltd (BBIL), a wholly owned subsidiary of Biocon, for $100 million, valui...

The IPO got bids for 1,60,79,700 shares against 1,60,00,000 shares on offer, resulting in a subscription of 1.01 (rpt) 1.01 times, accordin...

If you look at how the business model has evolved for Biocon, Syngene is the one which is driving the overall profitability for the company...

Biocon plans to raise Rs 550 crore by diluting 11% stake in Syngene through the Initial Public Offer. The proceeds will mostly go into fund...

Biocon's subsidiary Syngene has set the price band for its forthcoming IPO at Rs 240-250 per share that will open on July 27.

Syngene International, present in the contract services business, had filed its draft red herring prospectus (DRHP) with Sebi .

After surging 2.93 per cent to Rs 460 in intraday trade, shares of Biocon ended at Rs 453.75, up 1.53 per cent on the BSE.

The company plans to sell 22 mn equity shares, including reservation of up to two mn shares for Biocon shareholders.

Biocon surged over 3% in intraday trade on Thursday after the company filed prospectus for Syngene IPO on Wednesday to raise Rs 600 cr .

The QIP activity has taken off very well, says Diwan. Ashoka Buildcon has come to the market at the right time, he adds.

'Syngene is India’s leading research services company in discovery and development space, especially in the pharmaceutical sector,' says Ma...

Biotechnology major Biocon on Tuesday said it aims to achieve revenues of USD 1 billion in the next three years.

Biocon will launch an IPO for its fully-owned contract research subsidiary Syngene this financial year.